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Background
Duchenne muscular dystrophy (DMD) is a genetic neuro-
muscular disorder resulting in progressive muscle weakness 
and loss of skills, orthopedic abnormalities, and cardiac and 
respiratory insufficiencies. With improved medical interven-
tions and intensive health supports, individuals with DMD 
now live into their third decade, but disease progression is 
variable and difficult to predict.1–3 As a result, there is an 
increasing need for palliative care services that are today 
viewed as complementary to medical interventions.3–5
The current definitions of palliative care address much 
more than end-of-life care and include the early stages of a 
condition.4–7 Services typically considered as palliative 
include respiratory care to improve functioning and main-
tain quality of life, case management, counseling about 
decision-making as the disease progresses, legal planning 
like advanced directives, and other supportive services, all 
of which are critical in DMD.3,5,8–10 Despite the docu-
mented importance of palliative care overall, there has been 
some debate about its role in the care of individuals with 
neuromuscular disorders.11
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Abstract
Introduction: Information on use of palliative care services among individuals with Duchenne and Becker muscular 
dystrophy is scant despite the clearly documented need.
Methods: We examined associations between uptake of palliative care services by 233 males with Duchenne and Becker 
muscular dystrophy aged 12 and older for both caregiver and affected male characteristics using the Muscular Dystrophy 
Surveillance Tracking and Research Network baseline interview.
Results: Ninety-one percent of caregivers (213/233) used at least one palliative care service. Case management had the 
highest frequency of use (59%). Use of palliative care was more frequently associated with the characteristics of affected 
males, as were some individual palliative care services. Utilization of six individual services differed among Muscular Dystrophy 
Surveillance Tracking and Research Network sites. While research suggests that pain is a frequent problem in Duchenne and 
Becker muscular dystrophy, only 12.5% reported use of pain management services.
Discussion: Although palliative care use among families of males with Duchenne and Becker muscular dystrophy is high 
overall, there is much variability in use of individual services. Use of palliative care is driven by disease experience in the 
affected male. Many of the care recommendations for these individuals highlight the importance for early involvement of 
palliative care professionals.
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The study described herein extends our earlier research to 
quantify utilization of palliative care among families of indi-
viduals with DMD.11 Our current research includes families 
of individuals with DMD and Becker muscular dystrophy 
(BMD), a generally milder form of muscular dystrophy. The 
aims are to (1) describe palliative care services that families 
of a large cohort of males with DMD and BMD, hereafter 
DBMD, had ever received and (2) evaluate factors associ-
ated with utilization of services.
Methods
We utilized information collected through the Muscular 
Dystrophy Surveillance and Research Network (MD 
STARnet) baseline interview dataset. MD STARnet is a net-
work of six sites funded by the Centers for Disease Control 
and Prevention to conduct population-based surveillance and 
research for DBMD.12,13 Activities began in 2002 with four 
geographic regions of the United States (Arizona, Colorado, 
Iowa, and western New York). Two additional sites were 
subsequently added to the network: Georgia (2005) and 
Hawaii (2008). The surveillance methodology has been 
described elsewhere.13 Individuals with DBMD were 
included in the network if they were born on or after January 
1, 1982 and resided in one of the sites. Data were collected 
on individuals through death, out migration from the catch-
ment area, or the end of the surveillance project. Sites col-
lected data under a public health authority or Institutional 
Review Board (IRB) approvals.
The MD STARnet conducted a series of interviews, the 
first of which were baseline interviews of primary caregivers 
of 364 living or deceased males identified during the first 
two surveillance years (April 2004–August 2006) from 
Arizona, Colorado, Georgia, Iowa, and western New York. 
Hawaii did not participate in the interview component. Local 
IRB approval to conduct interview data collection with pri-
mary caregivers was obtained at each site separately from 
any surveillance approvals obtained. Written informed con-
sent was waived as all participants were contacted by mail 
and participated by phone. Interviews with primary caregiv-
ers were conducted during 2007–2012 and collected data on 
familial and socioeconomic characteristics, healthcare and 
other services received, including palliative care.12 Regarding 
palliative care, primary caregivers were asked to indicate if 
services had ever been received for the male with DBMD 
under their care. Sample size included parents of all indi-
viduals identified, abstracted, and classified as having 
DBMD, which was considered a population-based cohort. 
There were a total of 464 identified index males, of which 
419 were considered eligible for the survey.
Settings/subjects
Details of the MD STARnet survey sample and baseline 
interview have been reported previously.12 Data for the 
younger affected siblings were not included in the analyses 
to eliminate duplicate primary caregiver responses. We 
excluded one male who moved out of the United States and 
another who was determined not to have DBMD, resulting in 
a sample of 362 affected individuals and their primary car-
egivers. We excluded those affected males who were under 
the age of 12 years at the time of the interview, resulting in a 
total of 233 primary caregivers and affected individual pairs 
analyzed. The age exclusion allowed us to make our data 
comparable to those reported previously by our group11 and 
assess data for families whose children were likely at the 
stage of requiring supportive services, interventions, and 
other planning relevant to palliative care.
Measurements
The use of palliative care was measured as receipt of at 
least one palliative care service (hereafter palliative care 
use) and uptake of 14 individual services as reported by the 
affected males and their primary caregivers. The individual 
services included attendant care, case management, home-
maker services, mental health services, pastoral care, res-
pite care, social work, transportation, dietary services, 
home meals, hospice care, pain management, respiratory 
care, and skilled nursing.
Palliative care use and individual palliative services were 
evaluated in relation to selected characteristics of the affected 
males and primary caregivers in the families. Characteristics 
of the latter included age at interview (25–39/40–49/50–64), 
race/ethnicity as reported by the primary caregiver (white 
non-Hispanic/Hispanic/other), education (⩽high school/
some college or vocational/college graduate), household 
size, the MD STARnet site (Arizona/Colorado/Iowa/western 
New York), whether family had healthcare insurance (yes/
no), whether family had insurance denied (yes/no), current 
marital status if primary caregiver was the biological parent 
(single/married), whether primary caregiver works or goes to 
school (yes/no), and the number of hours the primary car-
egiver spends at work or school.
Characteristics of the affected males are variables describ-
ing their disease experience. They included person-years 
affected with disease (i.e. duration of disease), disease phe-
notype, use of a wheel chair, age when wheel chair was first 
used, use of noninvasive positive pressure ventilation 
(NIPPV) devices, age when NIPPV was first used, age when 
first had trouble walking or running, and age when first noted 
speech delay. Person-years with disease was calculated as 
the difference between age at interview and age at diagnosis. 
Disease phenotype was based on age of onset of signs and 
symptoms. Affected males who had signs and symptoms 
before their sixth birthday were classified as early onset. If 
the signs and symptoms started after the sixth birthday, then 
onset was classified as late.
Statistical analyses were conducted to examine associa-
tions between each characteristic and palliative care use, 
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following the descriptive approach in previous MD STARnet 
reports of services utilization.12,14 For palliative care use and 
individual service uptake, the comparison group included 
primary caregivers who reported no use of palliative care 
and those who reported no use of the individual service, 
respectively. T-tests and chi-square tests were used to test 
for differences in means and proportions, respectively. In all 
statistical tests, p-value <.05 was considered to be statisti-
cally significant.
Results
As reported previously, the response rate for the MD 
STARnet baseline interview was 53.8%, with respondents 
more frequently being mothers (87.5%), who were older, 
white non-Hispanic with at least a high school education.12 
The median age of the primary caregivers at interview in 
our sample was 45.8 years, and 45% reported family 
incomes greater than US$50,000. Among the 233 affected 
males in the analysis, 185 (79%) had early onset of signs 
and symptoms and the median ages at interview and at 
DBMD diagnosis were 17.8 and 5.0 years, respectively. The 
mean for person-years of disease was 12.9. Comparing the 
younger cases that were excluded from the analysis with 
the analytic dataset, we found that that primary caregiver’s 
median age at interview, affected male’s median age at 
interview, and person-years of disease were all predictably 
lower in the excluded cases. Families of excluded cases 
also had a higher proportion of incomes greater than 
US$50,000 (53.9% vs 45.0%). The analytic dataset included 
a higher proportion of individuals with the late-onset phe-
notype, which was also reflected in an older median age at 
diagnosis (5.0 vs 4.0 years).
Palliative care use
Among the 233 primary caregivers with valid data, 91% 
(213/233) reported palliative care use (Table 1). Of the pri-
mary caregivers reporting receipt of palliative care, more 
than half reported receipt of five or more individual services. 
Figure 1 presents the frequency of use for each service com-
pared to the previous study.11 Case manager services were 
the only services received by more than half of families. All 
remaining individual services were received by less than 
48% of families.
Associations between palliative care use and 
characteristics of respondents
Use of palliative care in relationship to the caregiver and 
affected male characteristics is shown in Table 1. No asso-
ciations were found between palliative care use and specific 
caregiver characteristics or MD STARnet site. However, 
users of palliative care were more likely to have lower fam-
ily income. Use of palliative care was not associated with the 
Table 1. Associations between selected affected male and 
caregiver characteristics and use of at least one palliative care 
services, MD STARnet baseline interview.
Characteristics Nonusers  
(N = 20)
n (%) or 
X ± SD
Use of service 
(N = 213)
n (%) or 
X ± SD
Predisposing characteristics  
Caregiver’s age at interview*  
 20–39 years 2 (10) 36 (19)
 40–49 years 11 (58) 116 (61)
 50 years or above 6 (32) 37 (20)
Caregiver’s race/ethnicity*
 Non-Hispanic White 16 (80) 143 (73)
 Hispanic 2 (10) 34 (17)
 Other 2 (10) 18 (9)
Caregiver’s education*
 High school or lower 4 (21) 66 (35)
 Some college 8 (42) 81 (43)
 Bachelor’s or higher 7 (37) 42 (22)
Household size 8.4 ± 21.4 3.8 ± 1.5
Enabling resources
MD STARnet site
 Arizona 3 (15) 50 (23)
 Colorado 4 (20) 46 (22)
 Georgia 8 (40) 38 (18)
 Iowa 1 (5) 41 (19)
 Western New York 4 (20) 38 (18)
Family income*†
 <US$30,000 3 (18) 73 (37)
 US$30,000–US$50,000 1 (6) 40 (20)
 >US$50,000 13 (76) 84 (43)
Family had insurance denied
 Yes 5 (25) 76 (36)
 No 15 (75) 133 (64)
Caregiver’s marital status
 Together 10 (71) 118 (73)
 Not together 4 (29) 43 (27)
Caregiver works or goes to school?
 Yes 15 (79) 115 (65)
 No 4 (21) 62 (35)
Caregiver hours spent at work/
school
36.1 ± 12 36.9 ± 17
Needs
Person-years of disease§ 10.7 ± 4.9 13.1 ± 4.4
Disease phenotype‡  
 Early-onset 11 (55) 173 (81)
Disease phenotype  
 Late-onset 9 (45) 40 (19)
Used wheel chair†
 Yes 9 (45) 197 (92)
 No 11 (55) 16 (8)
Age of first wheelchair use in years§ 11.9 ± 4.0 9.8 ± 2.6
Used NIPPV†
 Yes 1 (5) 86 (41)
 (Continued)
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Figure 1. Palliative care services ever received from the Arias et al.11 pilot and the MD STARnet interview data.
Characteristics Nonusers  
(N = 20)
n (%) or 
X ± SD
Use of service 
(N = 213)
n (%) or 
X ± SD
 No 19 (95) 125 (59)
Age when first used NIPPV in years –¶ 15.5 ± 3.1
Age when first had trouble walking/
running in years§
5.8 ± 3.4 4.0 ± 2.3
Age when first noted speech delay 
in years
2.4 ± 1.1 2.8 ± 1.6
Number of palliative care services used
 No services 20 (100)  
 1–2 services 55 (26)
 3–4 services 43 (20)
 5 or more services 115 (54)
Other information
Age of child in years at the time 
of interview or death if prior to 
interview
17.82 ± 4.30 18.11 ± 3.73
Age of child at DBMD diagnosis in 
years
7.07 ± 4.72 5.00 ± 2.81
Number of years between diagnosis 
and age at interview or death
10.75 ± 4.95 13.08 ± 4.37
DBMD: Duchenne and Becker muscular dystrophy; MD STARnet: Mus-
cular Dystrophy Surveillance, Tracking, and Research Network; NIPPV: 
noninvasive positive pressure ventilation.
*Chi-square test computed with new categories for caregiver’s age (20–
49 vs 50 years or above); caregiver’s race/ethnicity (non-Hispanic White 
vs others); caregiver’s education (high school or lower vs some college or 
more); family income (US$50,000 or less vs >US$50,000).
†Chi-square p-value <.01.
‡Chi-square p-value <.05.
§t-Test p-value <.05.
¶One case only, so data not shown.
Table 1. (Continued) age when NIPPV devices were first used or age when speech 
delay was first noted. Affected males who used palliative 
care had significantly longer duration of disease and were 
significantly younger when they first used a wheel chair and 
when they first experienced trouble walking/running than 
nonusers (Table 1). Those who used palliative care also were 
more likely to have the early-onset disease phenotype, use a 
wheel chair, and use NIPPV devices.
We assessed the relationship of the use of individual 
behavioral/social-related palliative care services with pri-
mary caregiver and affected male characteristics (Table 2). 
No significant associations were found between the use of 
individual services and primary caregiver’s age at interview, 
marital status, and household size, so these characteristics 
are not shown. Use of certain behavioral/social-related ser-
vices was significantly associated with indicators of socio-
economic status. Users of respite and transportation services 
were more likely to have lower education and for transporta-
tion less likely to be non-Hispanic white. Use of social work 
was more likely among lower-income families. Significant 
variation among sites for use of case management, home-
maker, respite care, and transportation was observed. With 
respect to characteristics of affected males, those who used 
mental health services had longer duration of the disease and 
were more likely to be using a wheel chair. Males who used 
pastoral care were those with longer disease duration. 
Families that used respite care were more likely to have a 
male using a wheel chair and NIPPV devices. Males who 
used attendant care and transportation services had longer 
disease duration and were more likely to use a wheel chair. 
Users of attendant care were also younger when they first 
used a wheel chair and were more likely to be using NIPPV 
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devices. Those who used homemaker services were more 
likely to be using NIPPV devices and were younger when 
they first experienced trouble walking or running. Use of 
case management was more likely in families of males who 
had longer disease duration, had the early-onset phenotype, 
were using a wheel chair and were younger when they first 
did so, were using NIPPV devices, and were younger when 
they first had trouble walking or running. Usage of social 
work was more likely when males had the early-onset phe-
notype, were using a wheel chair and were younger when 
they did so, and were using NIPPV devices.
Associations between health- and medical-related pallia-
tive services and primary caregiver and affected male char-
acteristics are shown in Table 3. Significant variation among 
MD STARnet sites was found for use of dietary and skilled 
nursing services. Use of both respiratory and skilled nursing 
services was more likely in lower-income families. Affected 
males who used dietary services were more likely to be using 
a wheel chair and NIPPV devices and were younger when 
they first experienced trouble walking or running. Users of 
pain management had a longer duration of the disease and 
were more likely to be using NIPPV devices. Finally, males 
who used both respiratory and skilled nursing services had 
experienced more years with the disease, were more likely to 
be using a wheel chair and were younger when this was first 
done, and were more likely to be using NIPPV devices.
Discussion
The sparse literature on palliative care use among individu-
als with DMD suggests that services are not recommended 
or utilized as much as they could be. Previous reports indi-
cate variable use of palliative care by individuals with DMD 
and their families as well as variation in the individual pallia-
tive care services used.10,11
We have described palliative care use as reported by 233 
primary caregivers of males with DBMD. Although use of 
any palliative care in our study was quite high (91%), there 
was considerable variability in usage of individual services. 
The number of services received ranged from 1 to 12 with a 
median of 4 out of 14 services listed (data not shown). Only 
one service, case management, was received by the majority 
of males with DBMD (59%); all others were received by 
less than half. Of note, the use of pain management services 
(12.6%) was the same as previously reported.11 This result 
remains of interest, as a comprehensive review of pain 
research in DMD concludes that it is a common problem in 
this population.15 The data suggest that pain may be treated 
by providers not associated with formal pain management 
services. Ironically, respiratory care and skilled nursing 
were reported less frequently than in our previous study 
despite the release of guidelines on respiratory care and 
monitoring in 2004.16
In our study, we found a significant association between 
the use of at least one palliative care service with lower 
income, which may be an artifact of the receipt of Medicaid 
versus private insurance coverage and costs. Similarly, use 
of respiratory care, skilled nursing, and social work were 
associated with lower income. Some other services had 
more frequent use among those who were Hispanic or other 
or had a high school education or less. These findings con-
trast with those of a previous MD STARnet study of com-
plementary and alternative medicine (CAM), which found 
CAM services were used more frequently in families where 
the primary caregiver was college educated and income 
was higher.12
One finding in need of further study is the variation 
among sites in the use of individual palliative care services. 
The current research extends that of Pandya et al.17 who 
found differences among MD STARnet sites in receipt of 
dietary and case management services in families of affected 
males across all ages. In our restricted range of affected 
males aged 12 and older, we found site differences for these 
same two services, as well as four additional palliative care 
services. Research has also identified MD STARnet site dif-
ferences in use of rehabilitative devices by affected males 
and the age when use of these devices was initiated.18
In our previous report,11 for all of the palliative care ser-
vices we examined, we found that service utilization is 
associated with the predisposing variable current age of the 
individual with DMD, irrespective of other factors we eval-
uated. In this new investigation, we have identified specific 
characteristics of affected males associated with use of pal-
liative care in general and for specific services. Across all 
characteristics we examined, there were significant associ-
ations of service usage with characteristics of affected 
males that reflect disease progression and severity, as 
would be expected in this population. Males with DBMD 
who used palliative care were those who had early onset of 
disease, were younger when they first had trouble walking 
or running, and had experienced more years with the dis-
ease. In addition, they were using a wheel chair and were 
younger when they first did so, and were using NIPPV 
devices. A similar pattern was found with individual pallia-
tive care services.
To our knowledge, our study is the first that utilizes a 
population-based sample of males with DBMD and their 
families to examine the palliative care use and factors associ-
ated with their use. Thus, these findings may be indicative of 
the utilization of palliative care in this population. Most of 
the previous studies have been based on small surveys.11
There are a number of limitations of the MD STARnet 
baseline survey including the response rate of just 53.8% and 
the possible influence of participation bias given that the 
respondents were older, non-Hispanic whites with more edu-
cation.12 There was potential recall bias given that informa-
tion was self-reported by primary caregivers who might not 
have remembered all of the palliative care services received. 
Another limitation is that we did not account for availability 
of palliative care services among MD STARnet sites. Also, 
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Andrews et al. 9
we did not inquire in the questionnaire whether palliative 
care services were offered to families by their care providers 
or whether they were offered but not available. Our sample 
selection could introduce some sampling bias due to the 
inclusion of a larger proportion of late-onset affected males 
who might demonstrate a milder phenotype, thereby reduc-
ing the need for some palliative care services. Understanding 
the reasons behind the lack of palliative care service uptake 
is a critical question to address in future research.
The earliest research on palliative and hospice care in 
individuals with advanced end-stage muscular dystrophy 
used qualitative methods to investigate commonalities in the 
need for palliative care.11 The early studies concluded that 
palliative care services for individuals with muscular dystro-
phy had not been sufficiently developed to be considered 
part of existing healthcare for these disorders. Our previous 
pilot of 34 families of young men with DMD demonstrated 
that families are not using palliative care and a need to 
improve awareness of these services.11 The current study 
provides population-based data on the largest sample to date 
of individuals with DBMD and their use of palliative care.
The use of palliative care in rapidly progressing conditions 
like DBMD provides families with numerous advantages. 
These include empowering a family to make decisions proac-
tively about how to handle specific disease progression limita-
tions (i.e. scoliosis surgery; tracheostomy); engaging the 
family in focusing on a long life rather than avoiding the dis-
cussion of future functional decline as a means for avoiding 
discussion of a child’s death; and assisting with care coordina-
tion, management, and informed decision-making.3,9,19
Conclusion
Our study presents data from a population-based sample of 
young men with DBMD and their families regarding their 
use of palliative care services. The data support the follow-
ing conclusions:
•• Although overall use of palliative care is high among 
families of males with DBMD, use of individual pal-
liative care services is extremely variable.
•• All but one of the individual palliative care services 
were used by less than 50% of families and 9 of the 14 
services were used by 37% or less families.
•• Use of palliative care services is associated with fewer 
predisposing and enabling characteristics such as pri-
mary caregiver’s education and family income than it 
is with the needs of affected males.
Palliative care services improve the quality of life for both 
caregiver and individuals with progressive conditions like 
DBMD. Our data suggest these services are underutilized 
among families of individuals with DBMD. Furthermore, our 
study points to a continuing need to educate healthcare pro-
viders and the public about palliative care and its capabilities 
for improving the quality of life among individuals with con-
ditions like DBMD and their families. Redefining the role of 
palliative care for life-limiting pediatric conditions and incor-
porating these services early on in the disease process within 
specialty clinics would be an important next step in the pro-
cess and would improve the understanding and awareness of 
available services. It would also foster proactive decision-
making for families who are taught to deal with their child’s 
disease progression as living with a progressive disease rather 
than reaching various phases of decline toward death.
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